EPISODE · Jul 8, 2021 · 30 MIN
Overcoming the Limitations of Conventional Cell Engineering
from RARECast
DNA-modified cells can behave unpredictably in the body and there is a risk that they could proliferate uncontrolled, cause severe toxicities, and even survive unchecked for months or years. Cartesian uses its platform technology to engineer RNA into cells, making time-controlled changes. The company is developing treatments for cancer, respiratory conditions, and autoimmune diseases such as myasthenia gravis. We spoke to Murat Kalayoglu, president and CEO of Cartesian, about its RNA-engineered cell therapies, how they work and how the company is pushing the use of cell therapies beyond cancer.
Embed this episode
What this episode covers
Murat Kalayoglu, president and CEO of Cartesian Therapeutics, discusses the company’s RNA-engineered cell therapies, how they work, and how the company is pushing the use of cell therapies beyond cancer.
NOW PLAYING
Overcoming the Limitations of Conventional Cell Engineering
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.